- EQRx and Absci Corporation ABSI have announced a discovery collaboration for protein-based therapeutics. Deal terms were not disclosed.
- The partnership will leverage Absci's Drug Creation technology for discovery and development activities, along with EQRx's clinical development expertise and commercial capabilities to advance protein-based therapeutics at more affordable costs for patients.
- EQRx and Absci will collaborate to jointly engineer and develop several clinical candidates across multiple therapeutic areas, including oncology and immunology.
- At Absci's option, it may make additional investments at progressive stages of development in exchange for an increased share of product sales.
- Price Action: ABSI stock closed 1.38% higher at $11.03 on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
